Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Avalo Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 28 | 32 | +4 |
| Shares | 5.55M | 9.13M | +3.58M (+64.5%) |
| Value | $28.0M | $16.0M | −$12.0M (−42.9%) |
New holders (8)
Institutions that held Avalo Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| VR Adviser, LLC | 1,000,000 | $1.75M | 0.34% |
| Great Point Partners LLC | 474,639 | $830.6K | 0.16% |
| Alyeska Investment Group, L.P. | 400,000 | $700.0K | 0.01% |
| Braidwell LP | 247,254 | $432.7K | 0.01% |
| Maven Securities LTD | 92,937 | $162.6K | 0.03% |
| Monashee Investment Management LLC | 60,000 | $105.0K | 0.03% |
| First Horizon Advisors, Inc. | 276 | $483 | 0.00% |
| JPMorgan Chase & Co | 101 | $0 | 0.00% |
Sold out (4)
Institutions that held Avalo Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Susquehanna International Group, LLP | 18,671 | $95.0K |
| Assenagon Asset Management S.A. | 15,646 | $79.0K |
| Clearstead Advisors, LLC | 27 | $136 |
| FMR LLC | 13 | $66 |